Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sinobiomed, a Chinese developer of genetically engineered recombinant protein drugs and vaccines, has appointed Brent Suen as its new director of strategic development.
Subscribe to our email newsletter
Mr Suen has 18 years of experience in the investment industry both as an investor and as an operator of companies. In 2002, Mr Suen assumed the role of interim CEO of Muse Communications, one of Elevation Capital’s portfolio companies. He led Muse through a global product launch and structured a strategic partnership with Fujitsu to integrate Muse into Fujitsu’s @Nifty portal.
In early 2003, at the invitation of Muse Communications’s angel investors, Mr Suen relocated to Hong Kong and joined IRG, Limited/IRG TMT Asia Fund. IRG TMT Asia Fund is an investor in Sinobiomed and Mr Suen joined the company in order to assist in the next phase of growth.
Banyun Yang, Sinobiomed’s CEO, said: “We welcome Mr Suen in an official capacity as director of strategic development. He’s been working with us in an unofficial capacity for several months and is also an investor in the company thru IRG.
“His activities on our behalf have included the introduction of the company to Lionel Choong, our new incoming CFO. We anticipate a number of relationships being forged on the funding and strategic partnership side in the near future and look forward with enthusiasm to Mr Suen’s involvement.”